JP2022062170A5 - - Google Patents

Download PDF

Info

Publication number
JP2022062170A5
JP2022062170A5 JP2022015456A JP2022015456A JP2022062170A5 JP 2022062170 A5 JP2022062170 A5 JP 2022062170A5 JP 2022015456 A JP2022015456 A JP 2022015456A JP 2022015456 A JP2022015456 A JP 2022015456A JP 2022062170 A5 JP2022062170 A5 JP 2022062170A5
Authority
JP
Japan
Prior art keywords
once
pharmaceutical composition
year
composition according
arc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022015456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022062170A (ja
Filing date
Publication date
Priority claimed from JP2020153037A external-priority patent/JP7021314B2/ja
Application filed filed Critical
Publication of JP2022062170A publication Critical patent/JP2022062170A/ja
Publication of JP2022062170A5 publication Critical patent/JP2022062170A5/ja
Priority to JP2023174548A priority Critical patent/JP7559175B6/ja
Pending legal-status Critical Current

Links

JP2022015456A 2016-02-12 2022-02-03 Hivおよびエイズの治療および予防方法 Pending JP2022062170A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174548A JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US62/294,576 2016-02-12
US201662297657P 2016-02-19 2016-02-19
US62/297,657 2016-02-19
JP2020153037A JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020153037A Division JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174548A Division JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Publications (2)

Publication Number Publication Date
JP2022062170A JP2022062170A (ja) 2022-04-19
JP2022062170A5 true JP2022062170A5 (cg-RX-API-DMAC7.html) 2022-07-14

Family

ID=58057333

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018541685A Active JP6810972B2 (ja) 2016-02-12 2017-02-10 Hivおよびエイズの治療および予防方法
JP2020153037A Active JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法
JP2022015456A Pending JP2022062170A (ja) 2016-02-12 2022-02-03 Hivおよびエイズの治療および予防方法
JP2023174548A Active JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018541685A Active JP6810972B2 (ja) 2016-02-12 2017-02-10 Hivおよびエイズの治療および予防方法
JP2020153037A Active JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174548A Active JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Country Status (37)

Country Link
US (4) US10537589B2 (cg-RX-API-DMAC7.html)
EP (1) EP3413897B1 (cg-RX-API-DMAC7.html)
JP (4) JP6810972B2 (cg-RX-API-DMAC7.html)
KR (4) KR20220126787A (cg-RX-API-DMAC7.html)
CN (2) CN108697727A (cg-RX-API-DMAC7.html)
AU (3) AU2017217656B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018016349A2 (cg-RX-API-DMAC7.html)
CA (1) CA3013473C (cg-RX-API-DMAC7.html)
CL (1) CL2018002150A1 (cg-RX-API-DMAC7.html)
DK (1) DK3413897T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2018000183A (cg-RX-API-DMAC7.html)
EA (1) EA201891814A1 (cg-RX-API-DMAC7.html)
ES (1) ES2953535T3 (cg-RX-API-DMAC7.html)
FI (1) FI3413897T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20217231B (cg-RX-API-DMAC7.html)
HR (1) HRP20230935T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063532T2 (cg-RX-API-DMAC7.html)
IL (1) IL260874B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20170038B1 (cg-RX-API-DMAC7.html)
LT (1) LT3413897T (cg-RX-API-DMAC7.html)
MD (1) MD3413897T2 (cg-RX-API-DMAC7.html)
MX (3) MX390604B (cg-RX-API-DMAC7.html)
MY (1) MY197090A (cg-RX-API-DMAC7.html)
NI (1) NI201800083A (cg-RX-API-DMAC7.html)
NZ (1) NZ745065A (cg-RX-API-DMAC7.html)
PH (1) PH12018501712A1 (cg-RX-API-DMAC7.html)
PL (1) PL3413897T3 (cg-RX-API-DMAC7.html)
PT (1) PT3413897T (cg-RX-API-DMAC7.html)
RS (1) RS64448B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201806783WA (cg-RX-API-DMAC7.html)
SI (1) SI3413897T1 (cg-RX-API-DMAC7.html)
SV (1) SV2018005733A (cg-RX-API-DMAC7.html)
TN (1) TN2018000267A1 (cg-RX-API-DMAC7.html)
TW (3) TWI822652B (cg-RX-API-DMAC7.html)
UA (1) UA126375C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017139519A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805073B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
CN109893536B (zh) * 2018-07-02 2021-04-27 河南真实生物科技有限公司 4’-取代核苷的晶型、制备和应用
WO2020018352A1 (en) 2018-07-17 2020-01-23 Merck Sharp & Dohme Corp. Hiv drug combination for increasing barrier against resistance
EP3897660A4 (en) * 2018-12-20 2022-09-07 Merck Sharp & Dohme Corp. NEW CRYSTALLINE FORMS OF AN NRTTI COMPOUND
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
PH12021500034A1 (en) 2019-03-06 2022-06-06 Glaxosmithkline Ip No 2 Ltd Compounds useful in hiv therapy
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
EP4358968A4 (en) * 2021-06-22 2025-05-07 Rome Therapeutics, Inc. 4-ETHINYL-3-HYDROXY-TETRAHYDROFURANYL ADENINE PHOSPHORAMIDATE AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2276404T3 (es) * 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
KR20110079783A (ko) 2003-02-19 2011-07-07 예일 유니버시티 항-바이러스 뉴클레오시드 유사체 및 바이러스 감염, 특히 에이치아이브이 감염의 치료방법
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US8513205B2 (en) * 2008-04-11 2013-08-20 Yale University Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
JP6768796B2 (ja) 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ウイルス薬を送達するための薬物送達システム
EP3471829A4 (en) * 2016-06-20 2020-01-15 Merck Sharp & Dohme Corp. ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
CN114206336A (zh) * 2019-08-13 2022-03-18 默沙东公司 用于递送抗病毒剂的药物递送系统
US20230149296A1 (en) * 2020-05-05 2023-05-18 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents and contraceptives
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Similar Documents

Publication Publication Date Title
JP2021001189A5 (cg-RX-API-DMAC7.html)
JP2022009090A5 (cg-RX-API-DMAC7.html)
JP2024133475A5 (cg-RX-API-DMAC7.html)
JP2024133474A5 (cg-RX-API-DMAC7.html)
RU2329050C2 (ru) Комбинация ингибиторов цитохром-р450-зависимых протеаз
HRP20230935T1 (hr) Postupci za liječenje i profilaksu hiv-a i aids-a
JP2020505423A5 (cg-RX-API-DMAC7.html)
JP2022537551A5 (cg-RX-API-DMAC7.html)
JP2019536805A5 (cg-RX-API-DMAC7.html)
JP2022527398A5 (cg-RX-API-DMAC7.html)
JP2018513188A5 (cg-RX-API-DMAC7.html)
RU2010104848A (ru) Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
JP2019517542A5 (cg-RX-API-DMAC7.html)
JP2016185995A5 (cg-RX-API-DMAC7.html)
RU2011127080A (ru) Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
RU2016114098A (ru) Новое производное аналога инсулина
JP2017514911A5 (cg-RX-API-DMAC7.html)
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
JP2023537921A5 (cg-RX-API-DMAC7.html)
JP2021004249A5 (cg-RX-API-DMAC7.html)
JP2022550828A5 (cg-RX-API-DMAC7.html)
JP2011500589A5 (cg-RX-API-DMAC7.html)
JP2025508098A5 (cg-RX-API-DMAC7.html)
CN104622927A (zh) 外用消炎粉
JP2019531286A5 (cg-RX-API-DMAC7.html)